Gilead Sciences

Gilead’s Yescarta extends survival in lymphoma study
Gilead’s Yescarta extends survival in lymphoma study
BioPharma Dive
Gilead Sciences
Yescarta
CAR-T
lymphoma
large B-cell lymphoma
Flag link:
Gilead gets big $175m judgment in HIV fraud case
Gilead gets big $175m judgment in HIV fraud case
Pharmaphorum
Gilead Sciences
HIV
fraud
legal
reimbursement
Flag link:
Gilead plans to invest $47M+ to boost its capacity in southern Ireland
Gilead plans to invest $47M+ to boost its capacity in southern Ireland
Endpoints
Gilead Sciences
Ireland
Flag link:
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Fierce Biotech
Big Pharma
Novo Nordisk
Moderna Therapeutics
Gilead Sciences
BeiGene
Flag link:
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
EP Vantage
GSK
Gilead Sciences
CROI
Cabenuva
HIV
Flag link:
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
Yahoo/Reuters
GSK
HIV
ViiV Healthcare
Gilead Sciences
Cabenuva
Biktarvy
Flag link:
Gilead Sciences reports positive data from HIV therapy trial
Gilead Sciences reports positive data from HIV therapy trial
Clinical Trials Arena
Gilead Sciences
lenacapavir
HIV
clinical trials
Flag link:
Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table
Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table
Fierce Pharma
Gilead Sciences
legal
HIV
antitrust
Teva Pharmaceutical
JNJ
Flag link:
Gilead reports positive data from urothelial cancer therapy trial cohorts
Gilead reports positive data from urothelial cancer therapy trial cohorts
Clinical Trials Arena
Gilead Sciences
Trodelvy
metastatic urothelial cancer
clinical trials
Flag link:
Gilead's Trodelvy snags vital breast cancer nod
Gilead's Trodelvy snags vital breast cancer nod
Fierce Pharma
Gilead Sciences
FDA
Trodelvy
breast cancer
HR-positive HER-negative breast cancer
Flag link:
Oncology, HIV sales lift Gilead’s revenues by 2%
Oncology, HIV sales lift Gilead’s revenues by 2%
Medical Marketing and Media
Gilead Sciences
earnings
HIV
oncology
hepatitis C
Flag link:
Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program
Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program
Fierce Biotech
Gilead Sciences
Matinas BioPharma
COVID-19
antivirals
Flag link:
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Gilead Sciences
CAR-T
Yescarta
UK
NICE
Kite Pharma
Novartis
blood cancer
Flag link:
Gilead Sciences to provide Trodelvy for Strata PATH trial
Gilead Sciences to provide Trodelvy for Strata PATH trial
Clinical Trials Arena
Gilead Sciences
Strata Oncology
Trodelvy
clinical trials
Flag link:
Gilead fosters growth with plans for new research center in California hometown
Gilead fosters growth with plans for new research center in California hometown
Fierce Biotech
Gilead Sciences
R&D
California
Flag link:
Big caps bounce back for biopharma
Big caps bounce back for biopharma
EP Vantage
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Flag link:
Three TIGIT players look to surprise in 2023
Three TIGIT players look to surprise in 2023
EP Vantage
anti-TIGIT
Roche
Merck
Gilead Sciences
Arcus Biosciences
Flag link:
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
BioPharma Dive
JPMHC 2023
vaccines
COVID-19
Moderna Therapeutics
Pfizer
Gilead Sciences
Flag link:
5 FDA decisions to watch in the first quarter
5 FDA decisions to watch in the first quarter
BioPharma Dive
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
Flag link:
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
BioPharma Dive
FDA
drug approvals
HIV
lymphoma
multiple sclerosis
Gilead Sciences
Roche
TG Therapeutics
Flag link:

Pages